NASDAQ:ARDXArdelyx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ardelyx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.06 +0.35 (+6.13 %) (As of 04/10/2020 01:45 PM ET) Add Compare Share Today's Range$5.72Now: $6.06▼$6.1750-Day Range$4.35MA: $6.20▼$8.7952-Week Range$2.10Now: $6.06▼$8.81Volume897,401 shsAverage Volume868,609 shsMarket Capitalization$398.75 millionP/E RatioN/ADividend YieldN/ABeta1.99 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Ardelyx has a potential upside of 98.0% from its current price of $6.06.Amount of Analyst CoverageArdelyx has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesArdelyx has received 470 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArdelyx has received 414 “underperform” votes. (Add your “underperform” vote.)Community SentimentArdelyx has received 53.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote “Outperform” if you believe ARDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $260,861.00 in company stock.Percentage Held by InsidersOnly 15.31% of the stock of Ardelyx is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to decrease by -10.38% in the coming year, from ($1.06) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.24 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDX Previous Symbol CUSIPN/A CIK1437402 Webhttp://www.ardelyx.com/ Phone510-745-1700Debt Debt-to-Equity Ratio0.27 Current Ratio11.34 Quick Ratio11.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.28 million Price / Sales75.52 Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book2.13Profitability EPS (Most Recent Fiscal Year)($1.47) Net Income$-94,940,000.00 Net MarginsN/A Return on Equity-95.83% Return on Assets-55.58%Miscellaneous Employees86 Outstanding Shares65,800,000Market Cap$398.75 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive ARDX News and Ratings via Email Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ARDX Rates by TradingView Ardelyx (NASDAQ:ARDX) Frequently Asked Questions How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)? Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARDX stock has increased by 1.3% and is now trading at $6.06. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Ardelyx? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx. When is Ardelyx's next earnings date? Ardelyx is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Ardelyx. How were Ardelyx's earnings last quarter? Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings data on Friday, March, 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.06. The biopharmaceutical company had revenue of $2.25 million for the quarter, compared to the consensus estimate of $0.70 million. View Ardelyx's earnings history. What price target have analysts set for ARDX? 5 equities research analysts have issued twelve-month price objectives for Ardelyx's shares. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 98.0% from the stock's current price. View analysts' price targets for Ardelyx. Has Ardelyx been receiving favorable news coverage? Headlines about ARDX stock have been trending very negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ardelyx earned a news impact score of -3.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutArdelyx. Who are some of Ardelyx's key competitors? Some companies that are related to Ardelyx include Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), SAGE Therapeutics (SAGE), Pacira Biosciences (PCRX), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), CytoDyn (CYDY), Ligand Pharmaceuticals (LGND), Karyopharm Therapeutics (KPTI), Innoviva (INVA), Heron Therapeutics (HRTX), Tricida (TCDA) and I-Mab (ARQT). What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Catalyst Pharmaceuticals (CPRX), BioCryst Pharmaceuticals (BCRX), Corbus Pharmaceuticals (CRBP), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and ImmunoGen (IMGN). Who are Ardelyx's key executives? Ardelyx's management team includes the following people: Mr. Michael G. Raab, Pres, CEO & Director (Age 54)Mr. David Rosenbaum, Chief Devel. Officer (Age 58)Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65) What is Ardelyx's stock symbol? Ardelyx trades on the NASDAQ under the ticker symbol "ARDX." How do I buy shares of Ardelyx? Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ardelyx's stock price today? One share of ARDX stock can currently be purchased for approximately $6.06. How big of a company is Ardelyx? Ardelyx has a market capitalization of $398.75 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 86 workers across the globe. View additional information about Ardelyx. What is Ardelyx's official website? The official website for Ardelyx is http://www.ardelyx.com/. How can I contact Ardelyx? Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Benefits of owning preferred stock
